Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 4/20 | 0.45 |
| ▸ | CCND1 | P24385 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200573 | 0.90 | HTR6 (0.57) | HTR6TRPV1LMNABAZ2BMAPT | |
| SCHEMBL7004630 | 0.83 | TRPV1 (0.74) | TRPV1CDK4CCND1DRD2 | |
| SCHEMBL6038429 | 0.83 | HTR6 (0.67) | HTR6BAZ2BMAPTHTR1ADRD2 | |
| SCHEMBL6196157 | 0.83 | HTR6 (0.53) | HTR6TRPV1LMNABAZ2BMAPT | |
| SCHEMBL6474459 | 0.82 | BAZ2B (0.62) | TRPV1LMNABAZ2BMAPTCDK4 | |
| SCHEMBL6483821 | 0.82 | BAZ2B (0.62) | TRPV1LMNABAZ2BMAPTCDK4 | |
| SCHEMBL6485981 | 0.82 | BAZ2B (0.62) | TRPV1LMNABAZ2BMAPTCDK4 | |
| SCHEMBL6474123 | 0.82 | TRPV1 (0.69) | TRPV1CDK4CCND1 | |
| SCHEMBL6492381 | 0.81 | CDK4 (0.63) | TRPV1LMNABAZ2BMAPTCDK4 | |
| SCHEMBL6038462 | 0.79 | HTR6 (0.57) | HTR6LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030109-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-6921823-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1196417-B8 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1196417-B1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | UPJOHN CO (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6878823-B2 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-12-09 | — | — | US | disclosed |
| WO-2004096809-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-B]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040054170-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-03-18 | — | — | US | disclosed |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA AND UPJOHN COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6468999-B1 | TREATING ANXIETY, DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS IN HUMANS AND ANIMALS | PHARMACIA & UPJOHN COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | disclosed |
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-08-15 | — | — | US | disclosed |
| EP-1196417-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005793-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 16/4885TRPV1 2539/4885LMNA 2724/4885 |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR6 19/4885TRPV1 1441/4885LMNA 3786/4885 |
| US-20040054170-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR6 19/4885TRPV1 1441/4885LMNA 3786/4885 |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 16/4885TRPV1 2539/4885LMNA 2724/4885 |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 17/4885TRPV1 2724/4885LMNA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.